Clinical Trial Update: Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) [Phase 3]

View source ↗

Summary

This clinical trial update indicates that Insmed's Treprostinil Palmitil Inhalation Powder (TPIP) is being studied in a Phase 3 trial for efficacy and safety in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Interstitial Lung Disease
• Pulmonary Hypertension

Drugs mentioned

• Treprostinil Palmitil Inhalation Powder (TPIP) (treprostinil palmitil inhalation powder)

Snippet

Sponsor: Insmed Incorporated | Conditions: Pulmonary Hypertension, Interstitial Lung Disease | Phase 3 | Status: RECRUITING